Previous 10 | Next 10 |
Lexicon Pharmaceuticals (NASDAQ: LXRX ) has officially regained all rights to diabetes med Zynquista (sotagliflozin) after its collaboration agreement with Sanofi (NASDAQ: SNY ) expired yesterday. More news on: Lexicon Pharmaceuticals, Inc., Sanofi, Healthcare stocks news, Read more ...
THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of Zynquista TM (sotagliflozin) and the settlement of its related disputes with S...
THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for Zynquista TM (sotagliflozin) will be presented at the upcoming European Association for the Study of Diabetes (EASD) 55 th annual meeting (Sept...
In March, the Food and Drug Administration issued a complete response letter -- the agency's euphemism for a rejection letter -- to Sanofi (NASDAQ: SNY) and Lexicon Pharmaceuticals (NASDAQ: LXRX) for their application to approve Zynquista as a treatment for type 1 diabetes. A few months...
THE WOODLANDS, Texas, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference: 2019 W...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) is up 4.6% after hours, rebounding off a 6.4% decline today, following disclosure that its president and CEO, Lonnel Coats, made several stock purchases over the past couple of business days. More news on: Lexicon Pharmaceuticals, Inc., Healthcare ...
Arcadia Biosciences (NASDAQ: RKDA ) +62% on USDA OK of drought-tolerant soybean strain. More news on: Arcadia Biosciences, Inc., Puma Biotechnology, Inc., Callaway Golf Company, Stocks on the move, Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) is up 7% premarket on light volume in response to pooled data from its inTandem1 and inTandem2 clinical trials evaluating Zynquista (sotagliflozin) in adult type 1 diabetics. The results were recently published in the journal Diabetes ...
Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes Results Recently Published in Diabetes Care THE WOODLANDS, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced p...
Beaten down biopharma Lexicon Pharmaceuticals ( LXRX +13.7% ) perks up on increased volume, bucking the broad market's sour mood. More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that senior company execut...
THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a...
THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., ...